Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
9.99
-0.10 (-0.99%)
Dec 5, 2025, 4:00 PM EST - Market closed
Aligos Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Cash & Equivalents | 41.95 | 37 | 135.7 | 81.35 | 186.82 | 220.38 | Upgrade
|
| Short-Term Investments | 57.15 | 19.94 | - | 44.48 | 3.92 | 23.13 | Upgrade
|
| Cash & Short-Term Investments | 99.1 | 56.94 | 135.7 | 125.83 | 190.73 | 243.51 | Upgrade
|
| Cash Growth | 32.27% | -58.04% | 7.85% | -34.03% | -21.67% | 106.96% | Upgrade
|
| Restricted Cash | 0.11 | 0.11 | 0.07 | 0.12 | 0.16 | 0.56 | Upgrade
|
| Other Current Assets | 4.23 | 5.09 | 5.31 | 7.6 | 13.53 | 5.94 | Upgrade
|
| Total Current Assets | 103.44 | 62.14 | 141.08 | 133.55 | 204.42 | 250.02 | Upgrade
|
| Property, Plant & Equipment | 5.62 | 7.33 | 9.82 | 12.51 | 14.97 | 14.91 | Upgrade
|
| Long-Term Investments | - | - | - | - | 15.11 | - | Upgrade
|
| Other Long-Term Assets | 0.71 | 0.63 | 0.63 | 0.63 | 0.87 | 0.38 | Upgrade
|
| Total Assets | 109.76 | 70.09 | 151.53 | 146.69 | 235.37 | 265.3 | Upgrade
|
| Accounts Payable | 4.65 | 2.57 | 2.52 | 4.74 | 3.02 | 3.31 | Upgrade
|
| Accrued Expenses | 13.61 | 15.56 | 16.84 | 16.04 | 25.39 | 16.56 | Upgrade
|
| Current Portion of Leases | 3.56 | 3.46 | 3.24 | 3.14 | 2.91 | 2.51 | Upgrade
|
| Current Unearned Revenue | 0.17 | 0.15 | 1.31 | 9.21 | 7.64 | 7.89 | Upgrade
|
| Total Current Liabilities | 21.99 | 21.74 | 23.91 | 33.13 | 38.96 | 30.27 | Upgrade
|
| Long-Term Leases | 2.5 | 4.92 | 7.9 | 9.43 | 11.55 | 10.5 | Upgrade
|
| Long-Term Unearned Revenue | - | - | - | 0.23 | - | 4.11 | Upgrade
|
| Other Long-Term Liabilities | 13.44 | 72.41 | 27.64 | - | 0.13 | 0.38 | Upgrade
|
| Total Liabilities | 37.93 | 99.07 | 59.45 | 42.79 | 50.64 | 45.26 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 693.69 | 588.58 | 578.33 | 502.61 | 487.35 | 394.96 | Upgrade
|
| Retained Earnings | -622.32 | -618.01 | -486.8 | -399.12 | -303.07 | -174.74 | Upgrade
|
| Comprehensive Income & Other | 0.46 | 0.45 | 0.55 | 0.4 | 0.45 | -0.19 | Upgrade
|
| Total Common Equity | 71.83 | -28.97 | 92.08 | 103.9 | 184.73 | 220.04 | Upgrade
|
| Shareholders' Equity | 71.83 | -28.97 | 92.08 | 103.9 | 184.73 | 220.04 | Upgrade
|
| Total Liabilities & Equity | 109.76 | 70.09 | 151.53 | 146.69 | 235.37 | 265.3 | Upgrade
|
| Total Debt | 6.07 | 8.38 | 11.14 | 12.57 | 14.46 | 13.01 | Upgrade
|
| Net Cash (Debt) | 93.03 | 48.56 | 124.57 | 113.25 | 176.28 | 230.51 | Upgrade
|
| Net Cash Growth | 41.41% | -61.01% | 9.99% | -35.75% | -23.52% | 123.07% | Upgrade
|
| Net Cash Per Share | 10.50 | 7.75 | 48.59 | 66.31 | 110.57 | 576.95 | Upgrade
|
| Filing Date Shares Outstanding | 6.15 | 6.11 | 3.03 | 1.72 | 1.71 | 1.53 | Upgrade
|
| Total Common Shares Outstanding | 6.15 | 3.86 | 3 | 1.72 | 1.71 | 1.52 | Upgrade
|
| Working Capital | 81.45 | 40.4 | 117.18 | 100.42 | 165.47 | 219.74 | Upgrade
|
| Book Value Per Share | 11.67 | -7.50 | 30.65 | 60.52 | 108.18 | 144.30 | Upgrade
|
| Tangible Book Value | 71.83 | -28.97 | 92.08 | 103.9 | 184.73 | 220.04 | Upgrade
|
| Tangible Book Value Per Share | 11.67 | -7.50 | 30.65 | 60.52 | 108.18 | 144.30 | Upgrade
|
| Machinery | 8.23 | 8.04 | 7.91 | 8.28 | 7.48 | 6.23 | Upgrade
|
| Construction In Progress | 0.16 | 0 | 0 | 0.02 | 0.02 | 0.07 | Upgrade
|
| Leasehold Improvements | 6.1 | 6.1 | 6.1 | 6.09 | 5.94 | 5.66 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.